Revised forecast
Fiscal year ending September 2027 · Second quarter (interim period) and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Impairment loss ¥224.951 million, impairment loss on investment securities ¥200.499 million, loss on disposal of fixed assets ¥10.042 million, loss on sale of fixed assets ¥43 thousand, total extraordinary losses ¥435.538 million
| Item | Details |
|---|---|
| Net Sales | Not disclosed → Second quarter (interim period) 16,000; full year 33,000 |
| Operating profit | Not disclosed → Second quarter (interim period) 800; full year 2,800 |
| Ordinary income | Not disclosed → Second quarter (interim period) 800; full year 2,800 |
| Profit attributable to owners of the parent | Not disclosed → Second quarter (interim period) △400; full year 700 |
| Net income per share | Not disclosed → Second quarter (interim period) △7.20; full year 12.60 |
| Fiscal Period Covered | Fiscal year ending September 2027 |
| Period Covered | Second quarter (interim period) and full year |
| Previous-period results | Consolidated for the fiscal year ended September 2026: revenue ¥31,105 million, operating profit ¥2,625 million, ordinary profit ¥3,055 million, net income attributable to owners of the parent ¥2,224 million, and net income per share ¥40.07 |
| Details and amount of extraordinary loss | Impairment loss ¥224.951 million, impairment loss on investment securities ¥200.499 million, loss on disposal of fixed assets ¥10.042 million, loss on sale of fixed assets ¥43 thousand, total extraordinary losses ¥435.538 million |
| Dividend forecast revision | Fiscal year ending September 2027: interim dividend ¥10, year-end dividend ¥10, annual dividend ¥20. Whether the forecast was revised: Not disclosed |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased in the fiscal year ended September 2026, driven by growth in sales from the healthcare business and the school DX business, but operating profit decreased due to higher development costs for the next-generation cloud-based electronic medical claims processing system and the cost burden of Lunaluna Mirai Support. Ordinary profit was flat as an increase in equity-method investment income offset other factors, while net income attributable to owners of the parent decreased mainly because extraordinary gains, including consumption tax refunds, declined. Going forward, the company says it will work to expand sales and profit in the school DX and healthcare businesses and increase the number of paying members in the content business.